Knowthestock.com
ARDX - Ardelyx Inc

Sell

Weak GrowthEarnings/Profit is Negative
WeakStrong
WeakStrong

35%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 127.33%
Operating Income is Negative but improving
Net Income is Negative but improving
Earnings Per Share (EPS) is Negative but improving
Net Margin is -14.86%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 4.12
Debt Ratio is 0.64
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.37
Cash Flow is WEAK
Cash from Operations is Negative but improving
Capital Expenditure not available
Net Increase in Cash is Negative
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Ardelyx Inc (ARDX) - https://www.ardelyx.com/
ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.
Exchange - NASDAQ
Industry - Research and Development in Biotechnology (except Nanobiotechnology)
Sector - Professional, Scientific, and Technical Services
CEO - Michael Raab
Employees - 200
    Close

    Login/Register

    Home


Cookie Policy
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.